| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18431 R78045 |
Lee (Controls exposed to TCAs), 2025 | Small for gestational age (birth weight <2 standard deviations below the mean for gestational age) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
1.01 [0.23;4.50] C excluded (control group) |
2/81 15/613 | 17 | 81 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18412 R77782 |
Lee (Controls unexposed, general pop), 2025 | Small for gestational age (birth weight <2 standard deviations below the mean for gestational age) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.08 [0.26;4.42] | 2/81 6,986/463,440 | 6,988 | 81 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18217 R76436 |
Martin, 2024 | Small for gestational age (SGA, defined as those with a birth weight in the lowest 10 percentiles for gestational age (<10th percentile) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.10 [1.05;1.16] | 2,008/17,599 229,066/2,408,707 | 231,074 | 17,599 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7696 R22826 |
Kivistö, 2016 | Small for gestational age ( birthweight < 10th centile) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.95 [0.59;1.55] | -/215 2,336/24,402 | - | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.10 [1.05;1.15] | 238,062 | 17,895 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 18431